- Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol.
- This finding with salmeterol is considered a class effect of LABA.
- The safety and efficacy of ANORA ELLIPTA, BREO ELLIPTA, OR TRELEGY ELLIPTA in patients with asthma have not been established. ANORA ELLIPTA, BREO ELLIPTA, OR TRELEGY ELLIPTA ARE not indicated for the treatment of asthma.
Patient Counseling Information
Updated January 2018